Fortress Biotech logo
Fortress Biotech
FBIO | NASDAQ
Chart Builder DCF Calculator
$1.71
-$0.17 (-9.04%)
At close: Nov 16, 2026, 4:00 PM ET
$1.71
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Fortress Biotech Company Profile

Company profile explained

Company Profile

Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.

Key Executives

Name Position
Lindsay Allan Rosenwald Executive Chairman, President & Chief Executive Officer
David Jin Chief Financial Officer & Head of Corporate Development
Michael S. Weiss Executive Vice Chairman of Strategic Development & Director
Xiaoqin Lu Chief Strategy Officer

Latest SEC Filings

Date Type Title
Oct 29, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 01, 2026 8-K Current Report
Oct 01, 2026 4 Filing
Sep 01, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 13, 2026 10-Q Quarterly Report
Aug 13, 2026 8-K Current Report
Jun 24, 2026 4 Filing
Jun 23, 2026 8-K Current Report
May 15, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
May 14, 2026 10-Q Quarterly Report
View All SEC Filings ➞
Fortress Biotech
Fortress Biotech logo
Country United States
IPO Date Nov 17, 2011
Industry Biotechnology
Sector Healthcare
Employees 78
CEO Lindsay A. Rosenwald

Contact Details

1111 Kane Concourse Bay Harbor Islands, Florida 33154 United States

Stock Details

Ticker Symbol FBIO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001429260
CUSIP Number 34960Q307
ISIN Number US34960Q3074
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.